WILMINGTON, Mass., Jan. 20, 2015 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB: IMSC), a leading manufacturer of
explosives trace detection (ETD) and drugs trace detection
solutions for homeland security applications, announced today that
Chief Operating Officer William
McGann has been named as the Company's Chief Executive
Officer, effective immediately. Dr. McGann replaces
Glenn D. Bolduc, who resigned his
position on 16 January 2015 as Chief
Executive Officer of the Company and his seat on the Company's
Board of Directors.
"Implant Sciences is a leader in developing innovative
capabilities, tools and solutions to counter the evolving terrorism
threats and help law enforcement curb drugs and narcotics. Implant
Sciences has built a world-class team and foundation of technology
and capabilities that enabled the company's B220 device to achieve
TSA approval and a purchase contract. Based on these
accomplishments, we look forward to pursuing the continued
expansion of our sales into new markets across the United States and internationally," stated
Dr. McGann.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 50 countries worldwide. The
Company's ETDs have received approvals and certifications from
several international regulatory agencies including the TSA in the
U.S., STAC in France, the German
Ministry of the Interior, and the Ministry of Public Safety in
China. It also received a GSN 2013 Homeland Security Award
for "Best Explosives Detection Solution". All Implant
Sciences products are recognized as Qualified Anti-Terrorism
Technologies by the Department of Homeland Security. For further
details on the Company and its products, please visit the Company's
website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking
statements," as that term is defined in the Private Securities
Litigation Reform Act of 1995. Such statements are based on
management's current expectations and are subject to risks and
uncertainties that could cause the Company's actual results to
differ materially from the forward-looking statements. Such risks
and uncertainties include, but are not limited to: the risk that
there is no guaranty that U.S. or foreign government and law
enforcement agencies or commercial consumers will purchase any of
our products or that any new products we may develop will be
accepted by the TSA or by such other governments, agencies or
consumers; economic, political and other risks associated with
international sales and operations could adversely affect our
sales; our business is subject to intense competition and rapid
technological change, and our success will depend on our ability to
develop and introduce new products; and other risks and
uncertainties described in our filings with the Securities and
Exchange Commission, including our most recent Forms 10-K, 10-Q and
8-K. Such statements are based on management's current expectations
and assumptions which could differ materially from the
forward-looking statements.
Implant Sciences Corporation
Company Contact:
Mike Turmell, Director
978-752-1700 x 116
or
Investor Contact:
Laurel Moody
646-810-0608
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/implant-sciences-board-announces-appointment-of-dr-william-mcgann-as-ceo-300022699.html
SOURCE Implant Sciences Corporation